The analyse of hemolysis-related indicators of newborn and control maternal-fetal Rh blood group incompatibility in the perinatal period and effective prevention
10.12025/j.issn.1008-6358.2017.20161020
- VernacularTitle:母儿Rh血型不合新生儿围产期溶血相关指标分析及防治
- Author:
Bi-Hui BAO
1
;
Hui-Fan LI
;
Zhong-Lan XU
;
Xiao-Fang WANG
;
Dan WANG
;
Qing CHANG
;
Xiao-Li YAN
;
He-Ying LIU
;
Qin CHEN
Author Information
1. 中国人民解放军陆军军医大学西南医院妇产科
- Keywords:
Rh blood group incompatibility;
hemolytic anemias;
hyperbilirubinemia;
newborn
- From:
Chinese Journal of Clinical Medicine
2017;24(4):630-634
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore specific indications of RH blood group incompatibility during perinatal period for effective prevention and timely treatment of haemolytic disease of fetus and newborn.Methods:46 maternal-fetal Rhesus incompatible newborns in recent three years were collected in southwest hospital of Army Medical University of PLA.A retrospective analysis of hemolysis-related indicators during perinatal period was performed between sensitized group and non-sensitized group,groups with blood transfusions and without blood transfusion,including anti-D antibody titre,hemoglobin,dynamical serum bilirubin value and so on.The clinical significance in the detected indexes were studied for treatment and the further preventions the associated complications.Objective:Of 46 infants,14 with severe anemia and/or hyperbilirubinemia treated by in-time exchange transfusion(ET)and plasma transfusion.12 infants of hyperbilirubinemia without obvious signs of hemolysis received complex management such as phototherapy,intravenous fluids and health support but ET.20 infants without existing alloantibodies didn't need any specific treatment.There were statistical differences in anti-D antibody titre,gestational age at birth,hemoglobin,serum-bilirubin,creatine kinase,creatine kinase isoenzyme among three groups(P<0.05).Conclusions:Intensive monitoring hematolytic indicators such as maternal anti-D antibody,fetal/neonatal hemoglobin and bilirubin can help find out newborns with severe alloimmune hemolytic disease and treat them timely.
